In vitro studies of 223Ra‑ and 225Ac‑labelled α‑zirconium phosphate as potential carrier for alpha targeted therapy
In this study suitability of α-ZrP nanoparticles as a 223Ra and 225Ac carriers for TAT was investigated. The yields of radiolabelling were higher than 98% in both cases. Subsequently, in vitro stability studies were carried out in various biological matrices during 48 h period. Measurements of released radioactivity showed the highest stability in saline. Released activity of 223Ra, 225Ac and their daughter radionuclides was around 0.5%. On the other hand, the lowest stability was shown in plasma and serum. Released activity for 223Ra, 225Ac and their progeny atoms was from 15 to 32%.
SAKMAR Michal;
ONDRAK Lukas;
FIALOVA Katerina;
VLK M.;
KOZEMPEL J.;
BRUCHERTSEIFER Frank;
MORGENSTERN Alfred;
2023-07-13
SPRINGER
JRC134374
0236-5731 (online),
https://link.springer.com/article/10.1007/s10967-022-08742-y,
https://publications.jrc.ec.europa.eu/repository/handle/JRC134374,
10.1007/s10967-022-08742-y (online),
Additional supporting files
| File name | Description | File type | |
|---|
